All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
Mutation in the Internal Tandem Duplication of the FMS-Like Tyrosine Kinase 3 (FLT3-ITD) gene is associated with poor survival outcomes and high relapse rates in Acute Myeloid Leukemia (AML) patients. Previous studies have demonstrated Allogeneic Stem Cell Transplantation (allo-SCT) in First Complete Remission (CR1) to be a curative option for younger patients below the age of 60 with AML. However, in older patients, there is a paucity of studies that investigated this effect, hence the rationale for this study.
Xavier Poiré from the Cliniques Universitaires Saint-Luc, Brussels, Belgium, and colleagues on behalf of the Acute Leukemia Working Party (ALWP) of the European Society Of Blood And Marrow Transplantation (EBMT), retrospectively analyzed the potential benefit of allo-SCT in patients ≥ 60 years with de novo FLT3-ITD AML. The results of the study were published in a recent edition of Haematologica.
Using the EBMT registry, the authors identified 291 intermediate-risk FLT3-ITD de novo AML patients (median age = 63.7 years) who underwent allo-SCT either from a related or unrelated donor between January 2000 and December 2015. Patients were transplanted either in CR1 (n = 212), Second Complete Remission (CR2, n = 37) or had Active Disease (AD) at the time of transplantation (n = 42). The endpoints of the study were Leukemia-Free Survival (LFS), Cumulative Incidence of Relapse (CIR), Non-Relapse Mortality (NRM), and GvHD-free/relapse free survival (GRFS) and Overall Survival (OS).
The authors noted that their study demonstrated that disease status at transplantation correlated with LFS, GRFS and OS. Thus, they recommended SCT as a consolidation strategy for fit ≥ 60-year-old patients with FLT3-ITD AML in CR1.
The authors stated that allo-SCT outcomes remain superior for older FLT3/ITD AML patients if the transplantation is being performed in CR1, similarly to previous observations in younger patients. They further concluded that “they do not recommend to postpone SCT till relapse in view of the inferior results observed when SCT is performed in CR2 and beyond.”. However, “they strongly recommend to offer SCT in early disease phase for every eligible patient with AML and FLT3-ITD as the best consolidation strategy”.
References